Investment analysts at HC Wainwright boosted their FY2027 EPS estimates for shares of Oncolytics Biotech in a research report ...

Equities researchers at HC Wainwright increased their FY2026 earnings estimates for shares of Oncolytics Biotech in a ...

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized ...

Oncolytics Biotech Inc. (ONCY) reported its Q4 2024 financial results, presenting a net loss of $8 million, compared to $3.9 million in the same quarter of the previous year. According to ...

BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancreatic ...

Full-Year Loss Per Share: $0.41 for 2024. Oncolytics Biotech Inc (NASDAQ:ONCY) reported outstanding final data in the BRACELET-1 breast cancer study, exceeding expectations. The company has ...

Oncolytics Biotech has a treatment in development for breast, pancreatic, and anal cancer. Pharmaceutical Executive spoke with chief medical officer Thomas C. Heineman, MD, PhD, and vice president of ...